Accessnewswire·2026-03-09 11:40Core Insights - Wellgistics Health, Inc. is targeting a significant market opportunity by launching Forzet™, a medical food aimed at addressing muscle loss associated with GLP-1 agonist therapies like Ozempic and Wegovy, which are projected to grow from $70 billion in 2025 to $201 billion by 2030 [1][2] Company Overview - Wellgistics Health, Inc. integrates an AI platform, EinsteinRx™, with a blockchain-enabled smart contracts platform, PharmacyChain™, to optimize pharmacy dispensing [1] - The company connects over 6,500 pharmacies and 200 manufacturers, providing end-to-end solutions in the U.S. prescription drug market [1] Product Launch - Forzet™ is classified as a medical food for dietary management of muscle loss and is available over the counter without a prescription [1] - The product has been evaluated in clinical studies involving patients with Type 2 diabetes, heart failure, and COPD [1] Market Dynamics - The GLP-1 agonist market is experiencing rapid growth due to increasing drug potency, convenient oral formulations, and rising interest from non-obese patients seeking weight loss alternatives [1] - Key limiting factors for market expansion include side effects such as muscle loss and gastrointestinal issues [1] Strategic Positioning - Wellgistics plans to leverage Forzet™ as an adjunct solution for patients on GLP-1 agonist drugs, utilizing its EinsteinRx hub technology at the point of sale [1] - The company aims to enhance its direct-to-consumer (DTC) offerings by integrating Forzet™ into its telehealth services [1]